Dexrazoxane
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Dexrazoxane and local guidelines before prescribing.
Cardioprotectant
Mechanism
Iron-chelating cardioprotectant.
Uses
Anthracycline cardiomyopathy prevention, extravasation.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Myelosuppression, nausea, injection-site pain.
Interactions
Cytotoxic additive.
Contraindications and cautions
Pregnancy
Monitoring
FBC, LVEF
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Reduce dose in renal impairment
Overdose and reversal
Supportive
Special advice
Start before anthracycline dose.
More from the textbook: uses, cautions and other points
- Treatment: ACE inhibitor/ARB and beta blocker for CTRCD; dexrazoxane can protect high-risk patients receiving anthracyclines; joint oncology decision on interruption.
Cardiology: Cardiomyopathies - Extravasation - leakage of a vesicant drug (e.g. anthracyclines, vinca alkaloids) causes pain and tissue necrosis. Stop the infusion, aspirate, and follow the protocol (e.g. dexrazoxane for anthracyclines).
Oncology: Principles - Follow the specific protocol - e.g. dexrazoxane and cold packs for anthracyclines; warm packs and hyaluronidase for vinca alkaloids.
Oncology: Emergencies - Dexrazoxane | Anthracycline extravasation.
Oncology: Emergencies
Where it is discussed in the book
- Cardiology: Cardiomyopathies (1 mention)
- Oncology: Principles (1 mention)
- Oncology: Emergencies (2 mentions)
- Integrated cardiology chapter (1 mention)